Cord blood metabolomics reveals gestational metabolic disorder associated with anti-thyroid peroxidase antibodies positivity

Lingna Han¹†, Xin Yang²†, Wen Wang², Xueliang Yang², Lina Dong², Shumei Lin*², Jianguo Li³⁴* and Xiaojing Liu²*

Abstract

Background: Thyroid disease is one of the common endocrine disorders affecting the pregnant women, in which thyroid autoimmunity can alter the progress and the outcome of pregnancy. Women with euthyroid status but anti-thyroid peroxidase (anti-TPO) antibodies positivity before pregnancy are prone to subclinical gestational hypothyroidism. However, the connections between anti-TPO antibodies positivity and gestational hypothyroidism remain largely unknown. The aim of the present study is to investigate the differences of fetal metabolic profile at birth according to maternal anti-TPO status.

Methods: We performed 1H-NMR metabolomics on cord blood of a nested case control cohort of 22 pregnant women with matched thyroid hormone levels and demographic data, including 11 women with euthyroid status but anti-thyroid antibodies positivity (into the anti-TPO antibodies positivity group) and 11 matched women as controls with euthyroid status and negative anti-thyroid antibodies (into the control group).

Results: Distinct metabolic profiles were observed between the anti-TPO antibody positivity group and the nested control group, from which a total of 10 metabolites with between-group altered abundances were structurally identified. Five out of the 10 metabolites were up-regulated in the anti-TPO antibodies positivity group, including D-Glucose, L-Glutamine, 3-Hydroxybutyric acid, Myo-Inositol, Creatinine. The other 5 metabolites were down-regulated in the anti-TPO antibodies positivity group, including L-Leucine, L-Lysine, L-Glutamic acid, L-Tyrosine, and L-Phenylalanine. All the 10 metabolites have been previously reported to be correlated with hypothyroidism. Metabolite set enrichment analysis and pathway analysis suggested that amino acid metabolism pathways (especially the phenylalanine metabolism) were associated with anti-TPO antibodies positivity.
Introduction
Gestational hypothyroidism (GH), as a common endocrine disorder in pregnant women, exerts a wide range of adverse maternal and fetal outcomes, including postpartum hemorrhage, miscarriage, low birthweight, preterm birth, respiratory distress, and risk for infectious morbidity of the offspring [1–6]. While a lot of attention has been focused on the routine screening, early confirmation of diagnosis and prompt treatment, the pathogenesis of GH remains largely undetermined. It is hypothesized that GH is developed due to thyroid regulatory mechanisms during pregnancy, inducing multiple pathophysiological insults in the hypothalamus–pituitary–thyroid axis [7].

Maternal factors are associated with gestational hypothyroidism, including maternal age, gestational diabetes mellitus, gestational age at antenatal visit, past obstetric history of miscarriages, and hypertension [2]. Anti-thyroid peroxidase (anti-TPO) antibodies positivity is one of the risk factors of GH, which is associated with higher TSH levels and higher risk of subclinical hypothyroidism [8]. Women with anti-TPO antibodies positivity before pregnancy are prone to develop GH [9]. It is believed that anti-thyroid antibodies positivity represents a generalized autoimmune imbalance that may be responsible for elevated complications despite the euthyroid status [10].

Metabolic syndrome is one of the representatives of increased complications in pregnant women with euthyroid status [11]. Metabolic syndrome is resulted from abnormal chemical reactions in the body, which contributes to numerous gestational diseases, including gestational diabetes mellitus [12], gestational hypertension [13], gestational hypothyroidism [14], etc. Metabolic disorder also exerts direct adverse effects to the progress and outcome of pregnancy [15]. Thus, more attention should be paid on the metabolic disorder induced by anti-thyroid antibodies positivity in the pregnant women with euthyroid status.

Metabolic adaptations represent a crucial part of pregnancy, providing sufficient energy to the mother to meet the demands of pregnancy. Aberrant metabolic adaptations result in metabolic disorders. Metabolic disorders during pregnancy are risk factors of pregnancy complications and postpartum cardiovascular diseases [16–18]. The maternal and fetal compartments are different and are separated by the placenta interface. The altered fetal metabolic status can drive various consequences, which is critical in gestational and postpartum health of mother and the fetus/offspring.

Many clinical factors could influence the metabolic status in pregnant women, including age [19], BMI (body mass index) [20], levels of TSH (thyroid stimulating hormone) [21, 22], FT3 (free triiodothyronine) or FT4 (free thyroxine) [23]. Complicated clinical manifestations confound the investigations in figuring out the role of anti-thyroid antibodies positivity [24, 25]. To investigate the differences of fetal metabolic profile at birth according to the status of maternal anti-TPO antibodies, we performed a 1H-NMR metabolic profiling of cord blood from a nested case control cohort with matched clinical status in the present study.

Materials and methods
Study design
We retrospectively assessed a prospectively collected cohort of pregnant women in the First Affiliated Hospital of Xi’an JiaoTong University, (Xi’an, PR China) between April and September of 2018. A cohort of 22 pregnant women with singleton pregnancy were enrolled, including 11 women with euthyroid status but anti-thyroid antibodies positivity (into the anti-TPO antibodies positivity group) and 11 matched women as controls with euthyroid status and negative anti-thyroid antibodies (into the control group). As an exploratory study, the sample size was determined based on available resources and logistic limitations (it is difficult to obtain a larger cohort of nested matched case & control for the investigation of anti-TPO antibodies positivity).

Written informed consent has been obtained from all the human participants. According to the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum [26], the threshold for anti-TPO antibodies positivity was set at 34 IU/ml, and euthyroid status was defined as normal levels of thyroid hormones (0.27 μIU/ml < TSH < 4.2 μIU/ml, 3.1 pmol/L < FT3 < 6.8 pmol/L, and 12 pmol/L < FT4 < 22 pmol/L). The controls were matched with the women with anti-TPO antibodies positivity by age, BMI, fasting blood glucose, TSH, FT3, FT4, gestational weeks of delivery, fetus number, birthweight and gender of the newborn (Table 1). Pregnant women with any known pre-existing thyroid dysfunction, impaired

Conclusion: The results of this study suggested that fetal metabolic disorder is correlated with anti-TPO antibodies positivity, representing by abundance alteration of hypothyroidism associated metabolites and the related disturbance of amino acid metabolism pathways.

Keywords: Anti-thyroid peroxidase antibodies positivity, 1H-NMR metabolomics, Amino acid metabolism
fasting glucose, abnormal liver, or kidney function were excluded. All the enrolled pregnant women exhibited no symptom of gestational diabetes or gestational hypertension. The study was performed in accordance with the Declaration of Helsinki, following the STROBE guidelines for reporting of observational studies [27], and had been approved by the Ethics Committee of the First Affiliated Hospital of Xi’an JiaoTong University.

Demographic data collection and clinical chemistry tests

Demographic data of the enrolled pregnant women were obtained by an interview during the 11th-13th weeks of gestation, including age, nationality, body weight, blood pressure and disease history. Fasting blood was collected simultaneously for the detection of TSH, FT3 and FT4. Cord blood was collected during birth-giving. Heparinized plasma was obtained by centrifuge of the collected blood samples at 3000 rpm for 5 min, aliquoted and stored in a -86°C deep freezer. Thyroid hormones and anti-TPO antibodies were measured with the fasting plasma collected during the 11th-13th weeks of gestation by a Cobas 6000 analyzer (Roche Diagnostics, Basel Switzerland) utilizing the electrochemiluminescence (ECL) technology. The levels of anti-TPO antibodies were determined by using the Roche Diagnostics COBAS Elecsys Anti-TPO performed with a Cobas 6000 analyzer according to the manufacture's instructions. Fasting blood glucose was measured by using an AU5800 Automatic Biochemical Analysis System (Beckman Coulter, CA, USA).

### Table 1

Demographic data and clinical chemistry test results for the enrolled pregnant women and the newborns in the present study

| Item                                           | Control group (mean ± s.d.) | Anti-TPO antibodies positivity group (mean ± s.d.) | p-value |
|------------------------------------------------|----------------------------|----------------------------------------------------|---------|
| Age (year)                                     | 29.42 ± 2.17                | 30.09 ± 3.08                                       | 0.26    |
| BMII of the pregnant women (Kg/m²)             | 26.29 ± 2.74                | 26.27 ± 3.48                                       | 0.76    |
| Fetus number (singleton/multiple pregnancies)   | 6/5                        | 9/2                                                 | 0.18 (χ² = 2.93)    |
| gestational weeks of delivery                   | 38.85 ± 0.95                | 38.91 ± 0.83                                       | 0.69    |
| TSH (μIU/ml)                                   | 2.20 ± 0.37                 | 2.28 ± 0.32                                        | 0.91    |
| FT3 (pmol/L)                                   | 4.78 ± 0.47                 | 4.85 ± 0.48                                        | 0.48    |
| FT4 (pmol/L)                                   | 15.59 ± 2.10                | 16.47 ± 2.57                                       | 0.30    |
| anti-TPO antibodies (IU/ml)                     | 15.11 ± 4.16                | 273.70 ± 168.50                                    | 0.00047 |
| FBG in the 11th gestational week (mmol/L)       | 4.65 ± 0.19                 | 5.18 ± 0.69                                        | 0.06    |
| FRG at delivery (mmol/L)                       | 4.44 ± 0.32                 | 4.91 ± 0.60                                        | 0.09    |
| Gender of the newborns (Male/Female)           | 5/6                        | 6/5                                                 | 0.39 (χ² = 0.78)   |
| Birthweight of the newborns (Kg) (Q1, Q2, Q3)   | 3.32 ± 0.35 (3.17, 3.38, 3.51) | 3.14 ± 0.21 (3.02, 3.09, 3.27)                  | 0.52    |

BMI: body mass index, TSH: thyroid stimulating hormone, FT3: free triiodothyronine, FT4: free thyroxine, FBG: fasting blood glucose

*a* The distribution of newborn weight was expressed by the first Quartile (Q1), the second Quartile (Q2), and the third Quartile (Q3)

* # The differences of fetus number* and newborn gender# between the case and the control group were tested by the chi-square test, respectively

**1H-NMR based metabolic profiling**

Cord blood sample preparation for 1H-NMR spectral profiling was performed according to a previously reported procedure [28]. Briefly, a volume of 450 μl sample was mixed with 900 μl methanol (HPLC grade), vortexed for 5 min and then centrifuged at 4°C, 15, 000 rpm for 20 min for protein precipitation. The supernatant was dried completely by a vacuum dryer (Concentrator plus, Eppendorf, Germany), and reconstituted in 600 μl phosphate buffer (0.2 M NaH₂PO₄/Na₂HPO₄ in D₂O, containing 10 mM TSP as internal standard, pD = 7.4). The reconstituted sample was then centrifuged at 4°C, 15, 000 rpm for 20 min to eliminate any precipitate. A volume of 550 μl of the supernatant was transferred into a 5 mm NMR tube for NMR spectral profiling. A Bruker 600 MHz AVANCE IIII NMR spectrometer (Bruker BioSpin, Germany) was applied for NMR spectral profiling, with the spectrum acquired by using the CPMG (Carr-Purcell-Merboom-Gill) pulse sequences. The parameters for CPMG were as follows: spectral width, 12,019.2 Hz; pulse width, 14 μs; spectral size, 65,536 points; relaxation delay, 1.0 s; number of scans, 64. MestReNova (v8.0.1) was applied for spectral data processing. The baseline and phase were corrected manually and the chemical shift of the internal standard TSP was calibrated at 0.00 ppm. The spectra region of δ 0.08 to δ 9.05 was segmented at 0.01 ppm width into NMR features with exclusion of the region of residual water (δ 4.63–δ 5.02).

Between-group differential NMR features were determined by the following criteria: Importance for the
Projection (VIP) ≥ 1 in the OPLS-DA model; false discovery rate (fdr)-adjusted P < 0.05 in between-group t test of the relative peak area of the NMR features; the absolute value of p(corr) in S-Plot analysis by SIMCA-P greater than 0.40 (determined by inquiring the critical value table of Correlation Coefficient Test). Metabolites were identified by searching the HMDB database (https://www.hmdb.ca) with the chemical shift and the coupling constant of the NMR features. Metabolic pathway prediction was performed by the implemented modules (the metabolite set enrichment analysis module and the pathway analysis module) in MetaboAnalyst [29] (v4.0, https://www.metaboanalyst.ca).

Multivariate statistical analysis
SIMCA-P (v14.1) was applied for multivariate statistical analysis of the metabolomic data. Principal component analysis (PCA) was performed for an overview of the metabolomic data and exclusion of any sample with abnormal value (determined by the Hotelling’s T2 range). Orthogonal projection to latent structures discrimination analysis (OPLS-DA) was applied to investigate the between-group variations by incorporating the classification information. A 200-cycle permutation test was performed to assess the fitness of the selected OPLS-DA model. The parameters multiple correlation coefficient (R2) and the cross-validated R2 (Q2) were applied for evaluating the fitting validity and the predictive ability of the selected OPLS-DA model, respectively. Data of metabolic profiling, clinical and demographic parameters were expressed as mean ± s.d. Mann–Whitney U test implemented in GraphPad Prism (v9.0.0) was applied for between-group statistical analysis unless otherwise specified. False discovery rate (FDR) was used as the post-hoc test method for multiple comparisons of the metabolic profiling data. p < 0.05 was considered statistically significant.

Results
Data pre-processing and quality control of the 1H-NMR metabolomics
Missing values of the metabolomic data were first detected by a data integrity check and were excluded with an in-house kept KNN (K-nearest neighbors) algorithm before subsequent analysis. The metabolomic data were then subjected to normalization procedures, including normalization by sum, log transformation, and Pareto scaling. A better distribution after normalization was observed (Figure S1). Quality control (QC) samples were applied to monitor the reproducibility of sample preparation and the robustness of instrument analysis. QC was performed by PCA on the tested samples and the QC samples (derived from a pool of aliquot from each sample). All the QC samples were clustered together in the sample space of PCA (Figure S2), suggesting good reproducibility and robustness of the metabolomic profiling.

Anti-thyroid antibodies positivity associated metabolic disorder in cord blood
We first performed PCA on the cord blood metabolome to evaluate the natural separation and to exclude any outliers (Figure S3a). Two principle components (PCs) were automatically selected, which explained 27% of the total variations (16.1 and 10.9% for PC1 and PC2, respectively). The metabolome of the control group clustered and showed a separation trend to that of the anti-TPO antibodies positivity group (Fig. 1a), indicating that metabolic disorders associated with anti-TPO antibodies positivity occurred.

To better discriminate the cord blood metabolome between the anti-TPO antibodies positivity group and the control group, we carried out a supervised OPLS-DA, incorporating the known sample classification information (Fig. 1b). The best-fitted OPLS-DA model was automatically selected, and then evaluated by a cross-validation of all available models using a 200-cycle permutation test (Figure S3b). The selected OPLS-DA model exhibited acceptable fit goodness (R2 = 0.54) and prediction ability (Q2 = -0.50). A clear separation was observed between the anti-TPO antibodies positivity group and the control group (Fig. 1b), confirming that fetal metabolic changes occurred in pregnant women with anti-thyroid antibodies positivity.

Identification of the altered cord blood metabolites associated with anti-TPO antibodies positivity
A total of 741 features were obtained from the 1H-NMR spectrum by binning in 0.01 ppm increments. Seventy nine out of the 741 features with altered between-group abundances (P < 0.05 in a Mann–Whitney U test) were divided into two clusters (Fig. 2a). One cluster of 40 features were enriched in the anti-TPO antibodies positivity group (the red rectangular box in Fig. 2a), while the other cluster of 39 features were enriched in the control group (the blue rectangular box in Fig. 2a). Thirty two out of the 79 features with between-group differential abundances were further selected by multiple testing adjustment according to the following criteria: VIP (Variable Importance for the Projection) >1 (Fig. 2b, Table S1); |p(corr)| (the absolute value of spearman rank correlation coefficient) >0.40 (Fig. 2c, Table S2); between-group fold change (FC) >2 and adjusted P <0.05 in Mann–Whitney U test (Fig. 2d, Table S3).

Ten metabolites were structurally identified from the 1H-NMR features with altered between-group
abundances (Table 2), including 60% (6/10) amino acids (L-Leucine, L-Lysine, L-Glutamic acid, L-Glutamine, L-Tyrosine, and Phenylalanine), 10% (1/10) monosaccharide (Glucose), 10% (1/10) liposoluble vitamin (Myo-Inositol), 10% (1/10) fatty acid derivate (3-Hydroxybutyric acid), and 10% (1/10) organic acid derivate (Creatine). The relative abundances of the identified metabolites demonstrated that 50% (5/10) metabolites (Fig. 3 a-e) were significantly up-regulated in the anti-TPO antibodies positivity group, including Glucose ($p < 0.01$), L-Glutamine ($p < 0.05$), 3-Hydroxybutyric acid ($p < 0.05$), Myo-Inositol ($p < 0.05$), and Creatinine ($p < 0.05$). And the other 50% (5/10) metabolites were significantly down-regulated (Fig. 3 f-j) in the anti-TPO antibodies positivity group, including L-Leucine, L-Lysine, L-Glutamic acid, L-Tyrosine, and L-Phenylalanine. These results suggested that anti-thyroid antibodies positivity was associated with metabolic disorder in cord blood, including metabolism of glucose, amino acids, and fatty acid derivate.

**Anti-thyroid antibodies positivity was associated with disturbance in amino acid metabolic pathways**

To infer the potential metabolic pathways underlying the altered metabolites associated with anti-thyroid antibodies positivity, we performed metabolite set enrichment analysis (MESA) and metabolic pathway analysis with the implemented modules in MetaboAnalyst web portal (https://www.metaboanalyst.ca). MESA is based on several libraries containing ~9,000 biologically meaningful metabolite sets collected primarily from human studies [29]. Nine metabolite sets were enriched by MESA of the 10 altered metabolites ($P < 0.05$, Fig. 4a, Table S4), including 5 (55.56%) amino acid metabolism related, 3 (33.33%) amino residue metabolism related, 2 (22.2%) glucose metabolism related, and 1 (11.11%) vitamin metabolism metabolite sets (Nicotinate and Nicotinamide Metabolism). Among the 5 amino acid metabolism related metabolite sets, phenylalanine and tyrosine metabolism, lysine degradation, and aspartate metabolism are about amino acid degradation, while glucose-alanine cycle is about conversion of amino acid to glucose, ammonia recycling is about recycling of ammonia into central amino acid metabolism. Of the 3 amino residue metabolism related metabolite sets, urea cycle is about excretion of ammonia, while ammonia cycling is about reuse of ammonia, and amino sugar metabolism is about the transfer of amine. Of the two glucose metabolism related metabolite sets, glucose-alanine cycle is about synthesis of glucose, while the Warburg effect is about metabolism of glucose. These results indicated that anti-TPO antibodies positivity associated with synthesis and metabolism of glucose; metabolism of phenylalanine, tyrosine, lysine, and aspartate; and the excretion and recycling of ammonia.

To further investigate the disturbed metabolic pathways associated with anti-thyroid antibodies positivity, we performed Metabolic Pathway Analysis, which integrated pathway enrichment analysis and pathway topology analysis based on >1600 pathways of 26 model organisms [29]. Seven metabolic pathways were significantly associated with anti-thyroid antibodies positivity (FDR-adjusted $p < 0.05$, Fig. 4b, Table S5), including phenylalanine, tyrosine and tryptophan biosynthesis, D-Glutamine and D-glutamate metabolism, phenylalanine...
Fig. 2  Identification of the cord blood metabolites with altered abundance associated with anti-TPO antibodies positivity. a Hierarchical clustering of the top 79 1H-NMR features with altered abundances in the anti-TPO antibodies positivity group. Euclidean distance and the Ward method were used to generate clustering tree. Abundances of the 1H-NMR features were displayed as colors ranging from red to blue as shown in the color bar (red, higher abundance; blue, lower abundance). b Variable Importance (VIP) plot of the top 39 1H-NMR features with VIP > 1. The horizontal axis represents the 1H-NMR features; the vertical axis represents the values of the corresponding 1H-NMR features. The columns were colored according to the values of spearman rank correlation coefficient as shown in the color bar. The identified metabolites with altered abundance in the anti-TPO antibodies group were labeled. The corresponding data are listed in Table S2. c S-Plot constructed from the OPLS-DA model shown in Fig. 1b, showing the covariance \( p(1) \) against the correlation coefficient \( p(\text{corr})[1] \) of the 1H-NMR features with altered abundances in the Anti-TPO antibodies positivity group. The solid cycles were colored according to the values of spearman rank correlation coefficient as shown in the color bar. The identified metabolites with altered abundance in the anti-TPO antibodies group were labeled. The corresponding data are listed in Table S2. d Volcano plot of the 1H-NMR features with between-group altered abundances. The horizontal axis displays the log twofold change (FC) value, and the vertical axis represents the value of log 10 FDR-adjusted \( p \) value. The thresholds were set at FC \( \geq 2 \), and FDR-adjusted \( P < 0.05 \). The blue and red circles denote the down- and up-regulated 1H-NMR features in the anti-TPO antibodies positivity group, respectively. The grey circles denote the 1H-NMR features without marked differences. The corresponding data are listed in Table S3.
metabolism, and arginine biosynthesis. From comparison of the results of MESA and pathway analysis, we proposed that anti-TPO antibodies positivity was associated with metabolic disorders in amino acid metabolism, especially in phenylalanine metabolism.

**Discussion**

Anti-TPO antibodies positivity contributes to GH, which is evidenced by its correlation with higher TSH levels and higher risk of subclinical hypothyroidism [8, 30], and by the fact that women with anti-TPO antibodies positivity before pregnancy are prone to develop GH [9]. However, little is known about the intermediates between Anti-TPO antibodies positivity and GH. In the present study, we performed 1H-NMR based metabolomics on cord blood from a nested case–control cohort of pregnant women to investigate the Anti-TPO antibodies positivity related metabolic changes, in order to bring insight into the connections between Anti-TPO antibodies positivity and GH.

Anti-TPO antibodies positivity was reported to have a higher prevalence in population with obese [31] and type 1 diabetes mellitus [32], and autoimmune thyroid dysfunction was associated with serum metabolomic changes, suggesting possible correlations between anti-TPO antibodies positivity and metabolic disorder.

### Table 2 Cord blood metabolites with altered abundances induced by anti-thyroid antibodies positivity

| Metabolite          | Chemical shift                                      | anti-TPO/Control                | VIP   | P(corrected) | FC    | p-value     | FDR-adjusted p-value |
|---------------------|-----------------------------------------------------|---------------------------------|-------|--------------|-------|-------------|----------------------|
| L-Leucine           | 0.948t, 1.700 m, 3.722m                               | 1.01 -0.42                      | 0.06  | < 0.01       | < 0.01|
| L-Lysine            | 1.46m, 1.71 m, 1.89 m, 3.02t, 3.74t                   | 1.35 -0.55                      | 0.18  | < 0.01       | < 0.05|
| D-Glucose           | 3.233dd, 3.398 m, 3.458 m, 3.524dd, 3.728 m, 3.824 m, 3.889dd, 4.634d, 5.223d | 5.51 0.63                       | 2.09  | < 0.01       | < 0.01|
| Creatinine          | 3.03s, 4.05s                                        | 1.02 0.59                       | 2.10  | < 0.01       | < 0.01|
| Myo-Inositol        | 3.268t, 3.524dd, 3.613t, 4.053t                       | 1.17 0.53                       | 4.61  | < 0.01       | < 0.01|
| 3-Hydroxybutyric acid | 1.204d, 2.314dd, 2.414dd, 4.160m                     | 3.44 0.81                       | 2.05  | < 0.01       | < 0.05|
| L-Glutaric acid     | 2.040m, 2.119m, 2.341 m, 3.748dd                      | 1.92 -0.76                      | 0.14  | < 0.05       | < 0.05|
| L-Glutamine         | 2.125 m, 2.446 m, 3.766t                              | 2.48 0.66                       | 5.82  | < 0.01       | < 0.05|
| L-Tyrosine          | 3.024dd, 3.170dd, 3.921dd, 6.877 m, 7.170 m          | 1.49 -0.69                      | 0.35  | < 0.01       | < 0.05|
| L-Phenylalanine     | 3.19m, 3.98dd, 7.32d, 7.36 m, 7.42 m                  | 1.46 -0.64                      | 0.16  | < 0.01       | < 0.01|

VIP: Variable Importance in the projection, FDR: false discovery rate, p(corrected): spearman rank correlation coefficient calculated with the principle component 1 of the selected OPLS-DA model, FC: Fold change, s: single peak, d: double peaks, t: triplet peaks, q: quarter peaks, m: multiple peaks.

Fig. 3 Relative abundance of the altered cord blood metabolites between pregnant women with anti-TPO antibodies positivity and the nested control: a D-Glucose, b L-Glutamine, c 3-Hydroxybutyric acid, d Myo-Inositol, e Creatinine, f L-Leucine, g L-Lysine, h L-Glutamic acid, i L-Tyrosine, j L-Phenylalanine. The relative abundance of a metabolite was defined as the corresponding peak area divided by the total peak area of one cord blood sample. The between-group statistic significance was calculated with Mann–Whitney test. * p < 0.05; ** p < 0.01.
A panel of 10 anti-TPO antibodies positivity related cord blood metabolites were identified in the present study, including 5 up-regulated and 5 down-regulated metabolites (Fig. 3, Table 2). Among the 5 up-regulated metabolites associated with anti-TPO antibodies positivity (including myo-inositol, glucose, L-glutamine, 3-hydroxybutyric acid and creatine), Myo-inositol was reported to be effective in maintaining the values of thyroid hormones (thus preventing subclinical hypothyroidism) [33] and in promoting iodine availability in thyrocytes (thus improving thyroid functionality) [34]. Maternal hyperglycemia was believed to be a risk factor for the development of thyroid autoimmunity [35]. While few connections between L-Glutamine and GH were reported, oral supplementation of glutamine was reported to reduce obesity and improve insulin sensitivity [36]. 3-hydroxybutyrate (the salt form of 3-hydroxybutyric acid) was reported to be increased in cats with overactive thyroid gland [37], and to act as a signal molecule regulating lipid metabolism and overall metabolic rate [38]. An elevated level of serum creatinine was observed in severe hypothyroidism [39]. Among the 5 down-regulated metabolites by anti-TPO antibodies positivity (including leucine, lysine, L-glutamic acid, L-tyrosine, and phenylalanine), Leucine was significantly decreased by hypothyroidism [40] and leucine supplementation was reported to improve effort tolerance of rat with hyperthyroidism [41]. Lysine deficiency contributes to disorder in plasma thyroid hormone through an elevation of FT3 [42]. Experimental hypothyroidism in rats resulted in decreased L-Glutamic acid [43], and Glutamic acid enhance thyroid stimulating hormone β subunit mRNA expression in the rat pars tuberalis [44]. Supplementation with L-Tyrosine is commonly used to support thyroid function, leading to a reduction in TSH [45, 46]. A low phenylalanine diet was report to contribute to subclinical iodine deficiency [47]. The fluctuations of all the ten metabolites induced by anti-TPO antibodies positivity in the present study were in accordance to their previously reported status in hypothyroidism, indicating that anti-TPO antibodies positivity contributes to a metabolic disorder prone to hypothyroidism.

Among the metabolic pathways associated with anti-TPO antibodies positivity observed in the present study,
amino acid metabolism occupied a dominant position (Fig. 4). Accordingly, amino acid metabolism pathways were reported to be potential drug targets in autoimmune diseases [48], and played an important role in immune responses by regulating T/B lymphocytes, cellular redox state, and antibodies production [49]. Several metabolic pathways observed in the present study were reported to be significantly altered in hypothyroidism, including the down-regulation of nicotinate and nicotinamide metabolism in hypothyroidism rats [50], the increased activity of urea cycle in animal models of hypothyroidism [51], the significantly altered phenylalanine, tyrosine and tryptophan biosynthesis in GH [28], the significantly increased phenylalanine metabolism in a hypothyroidism model [52]. While increased activity of the glucose-alanine cycle was beneficial in the control of glucose utilization without increasing the risk of hypoglycemia in hyperthyroidism [53], thyroid hormone enhanced the Warburg Effect in breast cancer [54]. Phenylalanine and tyrosine metabolism was associated with serum levels of TSH and FT4 [55], and was believed to be affected by TSH [56]. The above reports supported a conclusion that the anti-TPO antibodies associated amino acid metabolism pathways were correlated with hypothyroidism or thyroid hormones.

Besides the amino acid metabolism pathways associated with anti-TPO antibodies positivity, most of the other pathways (Fig. 4) were also related to amino acid. For example, ammonia recycling is responsible for recycling of ammonia into central amino acid metabolism [57]. Urea Cycle converts excess ammonia into urea in the mitochondria of liver cells [58]. Glucose-alanine Cycle refers to the series of reactions in which amino groups and carbons from muscle are transported to the liver [59]. From the results of MESA (Fig. 4a) and pathway analysis (Fig. 4b), we concluded that the anti-TPO antibodies positivity associated metabolic disorder contributed to hypothyroidism possibly through disturbance of amino acid metabolism in cord blood of pregnant women.

As a shortcoming of the present study, the number of enrolled cases is relatively small; this may result in false negative or false positive results due to the complicated physiological status among pregnant women. The fetal metabolic disorder associated with anti-TPO antibodies positivity may be affected by other clinical factors besides those included in the present study. Further large-scale studies are recommended to further explore the roles of anti-TPO antibodies positivity associated cord blood metabolic disorder observed in this study.

In summary, we performed 1H-NMR metabolomics on cord blood of a nested case–control cohort of 22 pregnant women to reveal the anti-TPO antibodies positivity associated fetal metabolic disorder. A panel of 10 metabolites with altered abundances was observed, all of which have been reported to be associated with hypothyroidism. The results of the present study suggested a correlation between anti-TPO antibodies positivity and fetal metabolic disorder, and called more attention to the clinical outcome of gestational anti-TPO antibodies positivity to both postpartum and the newborn health.

Abbreviations
1H-NMR: Hydrogen-1 Nuclear Magnetic Resonance; TSP: 3-Trimethylsilyl-
[2,2,3,3-D4]-Propionate; HMDB: Human Metabolome Database; VIP: Variable
Importance for the Projection; FDR: False Discovery Rate; PCA: Principal
Component Analysis; OPLS-DA: Orthogonal Projection to Latent Structures
Discriminant Analysis; anti-TPO: Anti-Thyroid Peroxidase; GH: Gestational
Hypothyroidism; BMI: Body Mass Index; TSH: Thyroid Stimulating Hormone;
FT3: Free Triiodothyronine; FT4: Free Thyroxine.

Supplementary Information
The online version contains supplementary material available at https://doi.
.org/10.1186/s12884-022-04564-8.

Additional file 1: Figure S1. Effects of normalization to the 1H-NMRme-
tabolomic profiling data. The normalization procedures implemented
in the MetaboAnalyst web portal (https://www.metabonanalyst.ca) was
applied for datanormalization, including sample normalization (normal-
ized by sum), datatransformation (log transformation), and data scaling
(mean-centered anddivided by the square root of the standard deviation
of each variable). Theleft panels represent the metabolomic data before
normalization, and the rightpanels represent the metabolomic data after
normalization.

Additional file 2: Figure S2. Quality control of the metabolomic profiling
based on PCA score plot. PCA was performed on the 1H-NMR metabo-
lomic profiling data of the clinical samples and the quality controls. The
blue solid circles denote the anti-TPO antibodies positivity group, the
green solid circles denote the nest control group, the red solid circles
denote the QCs. The ellipse represents the 95% confidence interval using
Hotelling’s T2 statistics.

Additional file 3: Figure S3. Hotelling’s T2 plot (a) and permutationtest
plot of the OPLS-DA model (b). (a) Hotelling’s T2 plot of the OPLS-DA
model (Figure1b) was generated by SIMCA-P. The x-axis denotes the 1H-NMR features, they-axis denotes the T2 Range. The red dash line
represents the 99% critical limit of T2, the yellow dash line represents the 95%
critical limit of T2. (b) Plot of R2Y and Q2 from a 200-step permutation
test to the OPLS-DA model. The y-axisshows the value of R2Y and Q2, the
x-axis shows the correlation coefficient between the observed and the
permuted data. The two points on the upper-right represent the R2Y and Q2
from the observed data set as labeled. The other points on thebottom-
left correspond to R2Y and Q2 from the permuted data sets.

Additional file 4: Table S1. The 1H-NMR metabolites with VIP > 1 correspond-
ing to Fig. 2b. Table S2. The 1H-NMR features with absolute pcorr value
> 0.40 corresponding to Fig. 2c. Table S3. Datacorresponding to the vol-
cano plot in Fig. 2d. Table S4. Metabolite set enrichment analysis results
corresponding to Fig. 4a. Table S5. The results of the metabolic pathway
analysis corresponding to Fig. 4b.

Authors’ contributions
X. L., J. L. and S. L. conceived and designed the research. L. H., X. Y. and W.W. processed the samples and analyzed the data. L. D. and L. H. conducted the
clinical sample collection. L. H. and X. Y. wrote the original draft. J. L. reviewed
the manuscript. All author(s) read and approved the final manuscript.
Funding
This work was supported by the National Major Science and Technology Project (No.2017ZX10021010 to L. H.); the Young Scientists Fund of the National Natural Science Foundation of China (No.81600951 to L. H., No.81301441 to J. L.), the Key R&D Plan of Shanxi Province (202003D31003/GZ to J. L.), the foundation of Shanxi Natural Science (No.201910D11468 to L. H.)

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.

Declarations

Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki. The experimental procedures were approved by the ethics committee of the First Affiliated Hospital of Xi’an Jiaotong University. All subjects participating in this study have signed informed consent form.

Consent for publication
Not applicable.

Competing interests
No potential conflicts of interest were disclosed by author.

Author details
1Department of Physiology, Changzhi Medical College, Changzhi 046000, People’s Republic of China. 2The First Affiliated Hospital of Xi’an JiaoTong University, 277 Yanta West Road, Xi’an 710061, People’s Republic of China. 3Institutes of Biomedical Sciences, Shanxi University, Taiyuan 030006, People’s Republic of China. 4Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, 92 Wucheng Road, Taiyuan 030006, People’s Republic of China.

Received: 22 September 2021 Accepted: 4 March 2022
Published online: 24 March 2022

References
1. Sahay RK, Nagesh VS. Hypothyroidism in pregnancy. Indian J Endocrinol Metab. 2012;16(3):364–70.
2. Kiran Z, Sheikh A, Malik S, Meraj A, Ismail S, Rashid MO, Shaikh Q, Majeed N, Sheikh L, et al. Maternal characteristics and outcomes affected by hypothyroidism during pregnancy (maternal hypothyroidism on pregnancy outcomes, MHPO-1). BMC Pregnancy Childbirth. 2019;19(1):476.
3. Lucaccioni L, Ficara M, Cenciarelli V, Berardi A, Predieri B, Iughetti L. Long term outcomes of infants born by mothers with thyroid dysfunction during pregnancy. Acta Biomed. 2020;2(1):e202101.
4. Behairi O, Walfisch A, Wainstock T, Szaingurten-Solodkin I, Landau D, Grzeskowiak LE, Leemaqz SY, Poston L, et al. Maternal thyroid peroxidase antibodies and pregnancy outcome in euthyroid women with antithyroid peroxidase antibodies on TSH levels of pregnant women and maternal-fetal complications. Endocrinol Diabetes Nutr (Engl Ed). 2018;65(8):444–50.
5. Yoshoka W, Amino N, Ida A, Kang S, Kudo T, Nishihara E, Ito M, Nakamura H, Mlyauchi A. Thyroxine treatment may be useful for subclinical hypothyroidism in patients with female infertility. Endocr J. 2015;62(1):87–92.
6. Rajput R, Yadav T, Seth S, Nanda S. Prevalence of thyroid peroxidase antibodies in pregnant women and maternal-fetal complications. Endocrinol Metab. 2012;16(3):364–70.
7. Mallawa Kankanamalage O, Zhou Q, Li X. Understanding the pathogenesis of gestational hypothyroidism. Front Endocrinol. 2021;12:653407.
8. Fernandez Martinez P, Pena Lopez-Carrasco G, Padilla M, Mehta R, Arriano-Campos O, Choza R, Sauque L, Garay-Sevilla M, Malacara JM, et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol. 2010;163(2):273–8.
9. Chazti L, Planas E, Pappas A, Alekgakis D, Karakosta P, Daraki V, Vassilaki M, Tsatsisnis C, Katatos A, Koutis A, et al. The metabolic syndrome in early pregnancy and risk of gestational diabetes mellitus. Diabetes Metab. 2009;35(6):490–4.
10. Phoswa WN, Khalil QP. The role of oxidative stress in hypertensive disorders of pregnancy (Preeclampsia, Gestational Hypertension) and metabolic disorder of pregnancy (Gestational Diabetes Mellitus). Oxid Med Cell Longev. 2021;2021:5581570.
11. Knight BA, Shields BM, Hattersley AT, Vaidya B. Maternal hypothyroxi-naemia in pregnancy is associated with obesity and adverse maternal metabolic parameters. Eur J Endocrinol. 2016;174(1):51–7.
12. Grieger JA, Gianella M, Gershowitz J, Beswick E, Mccowan LM, Kenny LC, Myers JE, Walker DJ, Dekker GA, et al. Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: A retrospective cohort of nulliparous women. PLoS Med. 2018;15(12):e1002710.
13. Vambergue A, Nuttens M, Goeurse P, Bausque S, Lepeur M, Fontaine P. Pregnancy induced hypertension in women with gestational carbohydrate intolerance: the diagast study. Eur J Obstet Gynecol Reprod Biol. 2002;102(1):31–5.
14. Dammi P, Houshmand-Oreagaa K, Kelstrup L, Lauenborg J, Mathiesen ER, Clausen TD. Gestational diabetes mellitus and long-term conse-quences for mother and offspring: a view from Denmark. Diabetologia. 2016;59(7):1396–9.
15. Gongora MC, Wengen NK. Cardiovascular Complications of Pregnancy. Int J Mol Sci. 2015;16(10):23905–28. Endocr Connect. 2018;7(3):E1–4.
16. Glastras S, Chen H, Pollock CA, Saad S. Maternal obesity increases the risk of metabolic disease and impacts renal health in offspring. Biosci Rep. 2018;38(2):BSR20180050.
17. He J, Lai Y, Yang J, Yao Y, Li Y, Teng W, Shan Z. The relationship between thyroid function and metabolic syndrome and its components: a cross-sectional study in a chinese population. Front Endocrinol. 2021;12:661160.
18. Ying H, Tang YP, Bao YR, Su XI, Cai X, Li YH, Wang DF. Maternal TSH level and TPOAb status in early pregnancy and their relationship to the risk of gestational diabetes mellitus. Endocrinol. 2016;54(3):742–50.
19. Tasset O, Abanuon GB, Yazici D, Tarsic D. Association of metabolic syndrome parameters with FT3 and FT4 ratio in obese Turkish popula-
tion. Metabol Syndr Relat Disord. 2012;10(2):137–42.
20. Tudos P, Varej R, Horhoianu J, Gicha C, Mateescu S, Dumitrac I, Matal-
eral and fetal complications of the hypothyroidism-related pregnancy. Maedica. 2010;5(2):116–23.
21. Balucan FS, Morshed SA, Davies TF. Thyroid autoantibodies in preg-
nancy: their role, regulation and clinical relevance. J Thyroid Res. 2013;2013:182472.
22. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grob-
man WA, Lauberg P, Lazarus JH, Mandel SJ, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid - official journal of the American Thyroid Association. 2017;27(3):315–89.
23. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies. Ann Intern Med. 2007;147(8):573–7.
24. Zhao C, Ge J, Jiao R, Li X, Li Y, Quan H, Yu T, Xu H, Li J, Guo Q, et al. 1H-NMR based metabolic profiling of cord blood in gestational hypothyroid-
ism. Annals of translational medicine. 2020;8(6):296.
25. Chang J, Soufan O, Li C, Caraus I, Li S, Bourque G, Wishart DS, Xia J. Meta- bioAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018;46(W1):W486–94.
30. Frohlich E, Wahl R. Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front Immunol. 2017;8:521.

31. Agbaht K, Mercan Y, Kutlu S, Alpdemir MF, Sezgin T. Obesity with and without metabolic syndrome: do vitamin D and thyroid autoimmunity have a role? Diabetes Res Clin Pract. 2014;106(1):27–34.

32. Vallianou N, Stratigou T, Koutroumpis S, Vassopoulou B, Tsagarakis S, Ioannidis G. Autoimmune thyroiditis in patients with type 1 diabetes mellitus: A long-term follow-up study. Diabetes & metabolic syndrome. 2019;13(1):608–11.

33. Porcaro G, Angelozzi P. Myo-inositol and selenium prevent subclinical hypothyroidism during pregnancy: an observational study. JIMD Rep. 2018;12:e164.

34. Barbaro D, Oru B, Unfer V. Iodine and Myo-Inositol: A Novel Promising Combination for Iodine Deficiency. Front Endocrinol. 2019;10:457.

35. Vitacolonna E, Lapolla A, Di Nenno B, Passante A, Buccu I, Giuliani C, Cerrone D, Capani F, Monaco F, Napolitano G. Gestational diabetes and thyroid autoimmunity. Int J Environ Res Public Health. 2012;9:867415.

36. Abboud KY, Reis SK, Martelli ME, Zordao OP, Tannihao F, de Souza AZZ, Assalin HB, Guadagnini D, Rocha GZ, Saad MA, et al. Oral Glutamine Supplementation Reduces Obesity, Pro-Inflammatory Markers, and Improves Insulin Sensitivity in Dio Wistar Rats and Reduces Waist Circumference in Overweight and Obese Humans. Nutrients. 2019;11(3):536.

37. Gorman L, Shackle LC, Armstrong PJ, Little K, Rendall A. Serum Beta Hydroxybutyrate Concentrations in Cats with Chronic Kidney Disease, Hypothyroidism, or Hepatic Lipidosis. J Vet Intern Med. 2016;30(2):611–6.

38. Meierziak J, Burgberger M, Wojtasik W. 3-Hydroxybutyrate as a Metabolite and a Signal Molecule Regulating Processes of Living Organisms. Biomolecules. 2021;11(3):402.

39. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159(1):79–82.

40. Rochon C, Taueron I, Dejax C, Benoit P, Tauveron I, Dejax C, Benoit P, Capitan P, Bayle G, Prugnaud J, Rochon C, Taueron I, Dejax C, Benoit P, Capitan P, Bayle G, Prugnaud J, et al. Response of leucine metabolism to hyperinsulinaemia in hypothyroid patients before and after thyroxine replacement. J Clin Endocrinol Metab. 2000;85(2):697–706.

41. Fidale TM, Antunes HKM, Roiever L, Goncalves A, Puga GM, Silva RPM, de Resende FN, de Souza FR, Fidale BM, Lizardo FB, et al. Leucine Supplementation Improves Effort Tolerance of Rats With Hypothyroidism. Front Physiol. 2018;9:1632.

42. Carew L, McMurtry J, Alster F. Effects of lysine deficiencies on plasma levels of thyroid hormones, insulin-like growth factors I and II, liver and body weights, and feed intake in growing chickens. Poult Sci. 2005;84(7):1045–50.

43. Golyanski M, Szpetnar M, Tatara M, Lutnicki K, Golynska M, Kurek L, Szczepanik M, Wilkolek P. Content of selected amino acids in the gastrocnenius muscle during experimental hypothyroidism in rats. J Vet Res. 2016;60:489–93.

44. Aizawa S, Sakai T, Sakata I. Glutamine and glutamic acid enhance thyroid-stimulating hormone beta subunit mRNA expression in the rat pars tuberalis. Endocrinol. 2012;212(3):383–94.

45. Kelleher AS, Clark RH, Steinbach M, Chace DH, Spitzer AR. Pediatrix Classic Parameters. J Clin Endocrinol Metab. 2018;103(5):2050–60.

46. Friedman N, Pioletz M, Caurant C, Thuessen BH, Hansen T, Wallachofski H, Grarup N, Skaby T, Budde K, Pedersen O, et al. Urinary metabolomics reveals glycemic and coffee associated signatures of thyroid function in two population-based cohorts. PloS one. 2017;12(3):e0173078.

47. Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Cliss CB, Haigis MC. Metabolic recycling of ammonia via glutamate dehydogenase supports breast cancer biomass. Science (New York, NY). 2017;358(6365):941–6.

48. Haskins N, Bhuvanendran S, Anselmi C, Gams A, Kanholm T, Kocher KM, LoTempio J, Krohmalny KI, Sohali D, Stearet N, et al. Mitochondrial Enzymes of the Urea Cycle Cluster at the Inner Mitochondrial Membrane. Front Physiol. 2020;11:542950.

49. Petersen KF, Dufour S, Cline GW, Shulman GI. Regulation of hepatic mitochondrial oxidation by glucol-alanine cycling during starvation in humans. J Clin Invest. 2019;129(11):4671–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedicalcentral.com/submissions